| 3/29/2018 | 300490000000 | FPA144 AND MODIFIED FOLFOX6 DOUBLE BLIND CONTROL IN PATIENTS WITH ADVANCED GASTRIC AND GASTROEESOPHAGEAL CANCER FPA144 20MG / ML PER VIAL 10X KIT FPA144 0 MG / ML LIQUID 20 ML PER VIAL 10X KIT
| 2 | Units | 20751.28 | N/A | ICON ANKARA KLINIK ARASTIRMA DIS TICARET ANONIM SIRKETI |
| 3/15/2024 | 300214000000 | PEMBROLIZUMAB 25MG/ML 4ML WITHDRAWABLE FROM THE STUDY COMPATING FIANLIMAB CEMIPLIMAB WITH +PEMBROLIZUMAB IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTIC MELANOMA | 4 | UNIT | 19382 | N/A | ICON ANKARA KLİNİK ARAŞTIRMA DIŞ TİCARET ANONİM ŞİRKETİ |
| 3/15/2024 | 300214000000 | PEMBROLIZUMAB 25MG/ML 4ML WITHDRAWABLE FROM THE STUDY COMPATING FIANLIMAB CEMIPLIMAB WITH +PEMBROLIZUMAB IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTIC MELANOMA | 6 | UNIT | 28720 | N/A | ICON ANKARA KLİNİK ARAŞTIRMA DIŞ TİCARET ANONİM ŞİRKETİ |
| 3/19/2024 | 300214000000 | PEMBROLIZUMAB 25MG/ML 4ML WITHDRAWABLE FROM THE STUDY COMPATING FIANLIMAB CEMIPLIMAB WITH +PEMBROLIZUMAB IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTIC MELANOMA | 10 | UNIT | 47649 | N/A | ICON ANKARA KLİNİK ARAŞTIRMA DIŞ TİCARET ANONİM ŞİRKETİ |
| 3/28/2024 | 300214000000 | PEMBROLIZUMAN 25MG/ML 4 ML WITHDRAWABLE FROM THE STUDY COMPATING FIANLIMAB CEMIPLIMAB WITH +PEMBROLIZUMAB IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTIC MELANOMA | 4 | UNIT | 19277 | N/A | ICON ANKARA KLİNİK ARAŞTIRMA DIŞ TİCARET ANONİM ŞİRKETİ |
| 3/19/2024 | 300214000000 | PEMBROLIZUMAB 25MG/ML 4ML WITHDRAWABLE FROM THE STUDY COMPATING FIANLIMAB CEMIPLIMAB WITH +PEMBROLIZUMAB IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTIC MELANOMA | 4 | UNIT | 19266 | N/A | ICON ANKARA KLİNİK ARAŞTIRMA DIŞ TİCARET ANONİM ŞİRKETİ |
| 3/20/2018 | 300490000000 | FPA144 AND MODIFIED FOLFOX6 DOUBLE BLIND CONTROL IN PATIENTS WITH ADVANCED GASTRIC AND GASTROEESOPHAGEAL CANCER FPA144 20MG / ML PER VIAL 10X KIT FPA144 0 MG / ML LIQUID 20 ML PER VIAL 10X KIT
| 1 | Units | 10460.11 | N/A | ICON ANKARA KLINIK ARASTIRMA DIS TICARET ANONIM SIRKETI |
| 3/18/2018 | 300490000000 | FPA144 AND MODIFIED FOLFOX6 DOUBLE BLIND CONTROL IN PATIENTS WITH ADVANCED GASTRIC AND GASTROEESOPHAGEAL CANCER FPA144 20MG / ML PER VIAL 10X KIT FPA144 0 MG / ML LIQUID 20 ML PER VIAL 10X KIT
| 1 | Units | 10448.45 | N/A | ICON ANKARA KLINIK ARASTIRMA DIS TICARET ANONIM SIRKETI |
| 3/19/2024 | 300214000000 | PEMBROLIZUMAN 25MG/ML 4 ML WITHDRAWABLE FROM THE STUDY COMPATING FIANLIMAB CEMIPLIMAB WITH +PEMBROLIZUMAB IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTIC MELANOMA | 4 | UNIT | 19251 | N/A | ICON ANKARA KLİNİK ARAŞTIRMA DIŞ TİCARET ANONİM ŞİRKETİ |
| 3/20/2018 | 300490000000 | FPA144 AND MODIFIED FOLFOX6 DOUBLE BLIND CONTROL IN PATIENTS WITH ADVANCED GASTRIC AND GASTROEESOPHAGEAL CANCER FPA144 20MG / ML PER VIAL 10X KIT FPA144 0 MG / ML LIQUID 20 ML PER VIAL 10X KIT
| 2 | Units | 20771.28 | N/A | ICON ANKARA KLINIK ARASTIRMA DIS TICARET ANONIM SIRKETI |